5EZL

Crystal Structure of Fab of parasite invasion inhibitory antibody c1 - monoclinic form

Summary for 5EZL

• Entry DOI: 10.2210/pdb5ezl/pdb
• Descriptor: Fab c12, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose, ... (5 entities in total)
• Functional Keywords: malaria inhibitory antibody, fab, immune system, cyrpa
• Biological source: Mus musculus (mouse); More
• Total number of polymer chains: 4
• Total formula weight: 95160.84

Authors

Favuzza, P.,Pluschke, G.,Rudolph, M.G. (deposition date: 2015-11-26, release date: 2017-01-11, Last modification date: 2024-11-20)

Primary citation

Favuzza, P.,Guffart, E.,Tamborrini, M.,Scherer, B.,Dreyer, A.M.,Rufer, A.C.,Erny, J.,Hoernschemeyer, J.,Thoma, R.,Schmid, G.,Gsell, B.,Lamelas, A.,Benz, J.,Joseph, C.,Matile, H.,Pluschke, G.,Rudolph, M.G.
Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibody.
Elife, 6:-, 2017

PubMed Abstract: Invasion of erythrocytes by merozoites is a composite process involving the interplay of several proteins. Among them, the Cysteine-Rich Protective Antigen (PfCyRPA) is a crucial component of a ternary complex, including Reticulocyte binding-like Homologous protein 5 (PfRH5) and the RH5-interacting protein (PfRipr), essential for erythrocyte invasion. Here, we present the crystal structures of PfCyRPA and its complex with the antigen-binding fragment of a parasite growth inhibitory antibody. PfCyRPA adopts a 6-bladed β-propeller structure with similarity to the classic sialidase fold, but it has no sialidase activity and fulfills a purely non-enzymatic function. Characterization of the epitope recognized by protective antibodies may facilitate design of peptidomimetics to focus vaccine responses on protective epitopes. Both in vitro and in vivo anti-PfCyRPA and anti-PfRH5 antibodies showed more potent parasite growth inhibitory activity in combination than on their own, supporting a combined delivery of PfCyRPA and PfRH5 in vaccines.

PubMed: 28195038
DOI: 10.7554/eLife.20383

Experimental method

X-RAY DIFFRACTION (2.43 Å)